相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
H. Hayashi et al.
ANNALS OF ONCOLOGY (2012)
Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points
A. Kay et al.
ANNALS OF ONCOLOGY (2012)
Cancer treatment and survivorship statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?
Eitan Amir et al.
EUROPEAN JOURNAL OF CANCER (2012)
Progression-Free Survival: Meaningful or Simply Measurable?
Christopher M. Booth et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
Kjell Magne Tveit et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
Eduardo Diaz-Rubio et al.
ONCOLOGIST (2012)
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J. Cassidy et al.
BRITISH JOURNAL OF CANCER (2011)
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
Ludwig Fischer von Weikersthal et al.
EUROPEAN JOURNAL OF CANCER (2011)
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer
Fotios Loupakis et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial
Michel Ducreux et al.
LANCET ONCOLOGY (2011)
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Richard A. Adams et al.
LANCET ONCOLOGY (2011)
Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
Katsuyuki Hotta et al.
PLOS ONE (2011)
Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
Everardo D. Saad et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Niall C. Tebbutt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study
F. -C. Bidard et al.
ANNALS OF ONCOLOGY (2009)
Worldwide Variations in Colorectal Cancer
Melissa M. Center et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
Benoist Chibaudel et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer.: EORTC study 40015
C.-H. Koehne et al.
ANNALS OF ONCOLOGY (2008)
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
B. Glimelius et al.
ANNALS OF ONCOLOGY (2008)
Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
S. Siena et al.
BRITISH JOURNAL OF CANCER (2007)
Progression-free survival is a surrogate for survival in advanced colorectal cancer
Marc Buyse et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy
Patricia A. Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer:: Final report of the Spanish cooperative group for the treatment of digestive tumors trial
Eduardo Diaz-Rubio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group
Rainer Porschen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
Miriam Koopman et al.
LANCET (2007)
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
Matthew T. Seymour et al.
LANCET (2007)
A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer
J. Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
Alfredo Falcone et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
J Souglakos et al.
BRITISH JOURNAL OF CANCER (2006)
Randomised phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
GAP Hospers et al.
ANNALS OF ONCOLOGY (2006)
OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer:: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986
CH Köhne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
G Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial
P Comella et al.
ANNALS OF ONCOLOGY (2005)
Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
HI Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
RM Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group
P Comella et al.
ANNALS OF ONCOLOGY (2002)
Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma:: A Southern Italy Cooperative Oncology Group phase II-III randomized trial
P Comella et al.
ANNALS OF ONCOLOGY (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)